Literature DB >> 25033747

Use of esmolol after failure of standard cardiopulmonary resuscitation to treat patients with refractory ventricular fibrillation.

Brian E Driver1, Guillaume Debaty2, David W Plummer3, Stephen W Smith3.   

Abstract

INTRODUCTION: We compare the outcomes for patients who received esmolol to those who did not receive esmolol during refractory ventricular fibrillation (RVF) in the emergency department (ED).
METHODS: A retrospective investigation in an urban academic ED of patients between January 2011 and January 2014 of patients with out-of-hospital or ED cardiac arrest (CA) with an initial rhythm of ventricular fibrillation (VF) or ventricular tachycardia (VT) who received at least three defibrillation attempts, 300mg of amiodarone, and 3mg of adrenaline, and who remained in CA upon ED arrival. Patients who received esmolol during CA were compared to those who did not.
RESULTS: 90 patients had CA with an initial rhythm of VF or VT; 65 patients were excluded, leaving 25 for analysis. Six patients received esmolol during cardiac arrest, and nineteen did not. All patients had ventricular dysrhythmias refractory to many defibrillation attempts, including defibrillation after administration of standard ACLS medications. Most received high doses of adrenaline, amiodarone, and sodium bicarbonate. Comparing the patients that received esmolol to those that did not: 67% and 42% had temporary return of spontaneous circulation (ROSC); 67% and 32% had sustained ROSC; 66% and 32% survived to intensive care unit admission; 50% and 16% survived to hospital discharge; and 50% and 11% survived to discharge with a favorable neurologic outcome, respectively.
CONCLUSION: Beta-blockade should be considered in patients with RVF in the ED prior to cessation of resuscitative efforts.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac arrest; Cardiopulmonary resuscitation; Defibrillation

Mesh:

Substances:

Year:  2014        PMID: 25033747     DOI: 10.1016/j.resuscitation.2014.06.032

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  8 in total

1.  2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.

Authors:  Ashish R Panchal; Katherine M Berg; Peter J Kudenchuk; Marina Del Rios; Karen G Hirsch; Mark S Link; Michael C Kurz; Paul S Chan; José G Cabañas; Peter T Morley; Mary Fran Hazinski; Michael W Donnino
Journal:  Circulation       Date:  2018-12-04       Impact factor: 29.690

2.  Sudden cardiac arrest in hypertrophic cardiomyopathy with dynamic cavity obstruction: The case for a decatecholaminisation strategy.

Authors:  Cosmin Balan; Adrian View-Kim Wong
Journal:  J Intensive Care Soc       Date:  2017-10-09

3.  First Report of Survival in Refractory Ventricular Fibrillation After Dual-Axis Defibrillation and Esmolol Administration.

Authors:  Kevin M Boehm; Daniel C Keyes; Laura E Mader; J Michelle Moccia
Journal:  West J Emerg Med       Date:  2016-10-20

4.  Refractory Ventricular Fibrillation Treated with Double Simultaneous Defibrillation: Pilot Study.

Authors:  Hee Eun Kim; Kui Ja Lee; You Hwan Jo; Jae Hyuk Lee; Yu Jin Kim; Joong Hee Kim; Dong Keon Lee; Dong Won Kim; Seung Min Park; Young Taeck Oh
Journal:  Emerg Med Int       Date:  2020-05-27       Impact factor: 1.112

5.  Esmolol for cardioprotection during resuscitation with adrenaline in an ischaemic porcine cardiac arrest model.

Authors:  Hilde Karlsen; Harald Arne Bergan; Per Steinar Halvorsen; Kjetil Sunde; Eirik Qvigstad; Geir Øystein Andersen; Jan Frederik Bugge; Theresa Mariero Olasveengen
Journal:  Intensive Care Med Exp       Date:  2019-12-04

Review 6.  The Evolving Role of Esmolol in Management of Pre-Hospital Refractory Ventricular Fibrillation; a Scoping Review.

Authors:  Dennis Miraglia; Lourdes A Miguel; Wilfredo Alonso
Journal:  Arch Acad Emerg Med       Date:  2020-02-25

7.  Feasibility of prehospital esmolol for refractory ventricular fibrillation.

Authors:  Casey Patrick; Remle P Crowe; Brad Ward; Ali Mohammed; Kelley Rogers Keene; Robert Dickson
Journal:  J Am Coll Emerg Physicians Open       Date:  2022-04-09

8.  The first case series analysis on efficacy of esmolol injection for in-hospital cardiac arrest patients with refractory shockable rhythms in China.

Authors:  Rui Lian; Guochao Zhang; Shengtao Yan; Lichao Sun; Wen Gao; Jianping Yang; Guonan Li; Rihong Huang; Xiaojie Wang; Renyang Liu; Guangqing Cao; Yong Wang; Guoqiang Zhang
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.